Delivering on HopeTM

Clinical Trials

Clinical Trials In Chorea In Huntington Disease

Neurocrine Biosciences is currently conducting KINECT-HD, a multi-center randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy, safety and tolerability of valbenazine for the treatment of chorea in patients with Huntington disease (HD). HD is a hereditary progressive neurodegenerative disorder, in which neurons within the brain break down, resulting in motor, cognitive and psychiatric symptoms. For more information on this Phase III study of valbenazine for the treatment of chorea in HD, please visit HuntingtonStudyGroup.org or clinicaltrials.gov.